The prolonged QT interval: Role of pro-inflammatory cytokines, reactive oxygen species and the ceramide and sphingosine-1 phosphate pathways

In Vivo

Volumn 29, Issue 6, 2015, Pages 619-636

  Sordillo, Peter P ^a   Sordillo, Diana C ^a   Helson, Lawrence ^a  

^a SignPath Pharma Inc   (United States)

Author keywords

Ceramide; Cytokines; hERG; Inflammation; Interleukin 1 ; Interleukin 6; Potassium channel; Prolonged QT; Reactive oxygen species; Repolarization; Review; Sphingosine 1 phosphate; TNF ; Ventricular arrhythmia

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; CERAMIDE; CRIZOTINIB; CURCUMIN; CYTOKINE; FATTY ACID; INTERLEUKIN 1BETA; NILOTINIB; PITAVASTATIN; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 6; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; TUMOR NECROSIS FACTOR;

CLINICAL TRIAL (TOPIC); DRUG INDUCED DISEASE; GENE OVEREXPRESSION; HUMAN; LIPIDOSIS; LONG QT SYNDROME; NONHUMAN; PROTEIN FUNCTION; QT PROLONGATION; REVIEW; ANALOGS AND DERIVATIVES; COMPLICATION; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART VENTRICLE; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PSORIASIS; RHEUMATOID ARTHRITIS;

ARRHYTHMIAS, CARDIAC; ARTHRITIS, RHEUMATOID; CYTOKINES; ELECTROCARDIOGRAPHY; HEART VENTRICLES; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LYSOPHOSPHOLIPIDS; PSORIASIS; REACTIVE OXYGEN SPECIES; SPHINGOSINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958164013     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Review

References (271)

1. Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, Rentfro A, McCormick JB and Fisher-Hoch SP: Type-2 diabetes is associated with elevated levels of TNFα, IL6 and adiponectin and low levels of leptin in a population of Mexican Americans: A cross-sectional study. Cytokine 57: 136-142, 2012.
2. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J and Hermann N: A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68: 930-941, 2010.
3. Nielsen OH and Ainsworth MA: Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 360: 754-762, 2013.
4. Sordillo PP and Helson L: Curcumin and cancer stem cells: Curcumin has asymmetrical effects on cancer and normal stem cells. Anticancer Res 35: 599-614, 2015.
5. Clark IA: The advent of the cytokine storm. Immunol Cell Biol 85: 271-273, 2007.
6. D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA and Clark GC: Targeting the 'cytokine storm' for therapeutic benefit. Clin Vaccine Immunol 20: 319-327, 2013.
7. Sordillo PP and Helson L: Curcumin suppression of cytokine release and cytokine storm. A potential therapy for patients with Ebola and other severe viral infections. In Vivo 29: 1-4, 2015.
8. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R and Bekker P: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50: 1412-1419, 2004.
9. Kaneko A: Tocilizumab in rheumatoid arthritis: Efficacy, safety and its place in therapy. Ther Adv Chronic Dis 4: 15-21, 2013.
10. Tobin AM and Kirby B: TNFα inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 19: 47-57, 2005.
11. Morita H, Wu J and Zipes DP: The QT syndromes: Long and short. Lancet 372: 750-763, 2008.
12. Hunter JD, Sharma P and Rathi S: Long QT syndrome. Contin Educ Anaesth Crit Care Pain 8: 67-70, 2008.
13. Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA and Christiansen M: The genetic basis of long QT and short QT syndromes: A mutation update. Human Mutat 30: 1486-1511, 2009.
14. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE and Vardas PE: Mechanisms, risk factors, and management of acquired long QT syndrome: A comprehensive review. Sci World J 2012: 212178, 2012.
15. Kannankeril P, Roden DM and Darbar D: Drug-induced long QT syndrome. Pharmacol Rev 62: 760-781, 2010.
16. Lazzerini PE, Acampa M, Capecchi PL, Hammoud M, Maffei S, Bisogno S, Barreca C, Galeazzi M and Laghi-Pasini F: Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. Eur J Intern Med 24: 368-374, 2013.
17. Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M and Laghi-Pasini F: Arrhythmic risk in rheumatoid arthritis: The driving role of systemic inflammation. Autoimmun Rev 13: 936-944, 2014.
18. Panoulas VF, Toms TE, Douglas KM, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A and Kitas GD: Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: An association driven by high inflammatory burden. Rheumatol 53: 131-137, 2014.
19. Chauhan K, Ackerman M, Crowson CS, Matteson EL and Gabriel SE: Population-based study of QT interval prolongation in patients with rheumatoid arthritis. Clin Exp Rheumatol 33: 84-89, 2015.
20. Simsek H, Sahin M, Akyol A, Akdag S, Ozkol HU, Gumrukcuoglu HA and Gunes Y: Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. Sci World J 2013: 901215, 2013.
21. Bourre-Tessier J, Clarke AE, Huynh T, Bernatsky S, Joseph L, Belisle P and Pineau CA: Prolonged corrected QT interval in anti-Ro/SSA-positive adults with systemic lupus erythematosus. Arthritis Care Res 63: 1031-1037, 2011.
22. Cardoso CR, Sales MA, Papi JA and Salles GF: QT-interval parameters are increased in systemic lupus erythematosus patients. Lupus 14: 846-852, 2005.
23. Bourre-Tessier J, Urowitz MB, Clarke AE, Bernatsky S, Krantz MJ, Huynh T, Joseph L, Belisle P, Bae SC, Hanly JG, Wallace DJ, Gordon C, Isenberg D, Rahman A, Gladman DD, Fortin PR, Merill JT, Romero-Diaz J, Sanchez-Guerrero J, Fessler B, Alarcon GS, Steinsson K, Bruce IN, Ginzler E, Dooley MA, Nived O, Sturfelt G, Kalunian K, Ramos-Casals M, Petri M, and Zoma A: Electrocardiographic findings in systemic lupus erythematosus: Data from an international inception cohort. Arthritis Care Res 67: 128-135, 2015.
24. Milovanovic B, Stojanovic L, Milicevik N, Vasic K, Bjelakovic B and Krotin M: Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death risk. Srp Arh Celok Lek 138: 26-32, 2010.
25. Curione M, Aratari A, Amato S, Colotto M, Barbato M, Leone S, Tego A, Panetti D and Parlapiano C: A study on QT interval in patients affected with inflammatory bowel disease without cardiac involvement. Intern Emerg Med 5: 307-310, 2010.
26. Sareli P, Schamroth CL, Passias J and Schamroth L: Torsade de pointes due to coxsackie B3 myocarditis. Clin Cardiol 10: 361-362.
27. Jensen TB, Dalsgaard D and Johansen JB: Cardiac arrest due to torsades de pointes ventricular tachycardia in a patient with Lyme carditis. Ugeskr Laeger 176, 2014.
28. Mitamura E, Mifune J, Kanamori K, Hifumi N, Shimizu O, Yamamura I, Takahashi Y, Oonaka M, Tanaka T and Nunoda S: A case of torsade de pointes tachycardia complicating diphtheria. Kokyu To Junkan 33: 223-228, 1985.
29. Badorff C, Zeiher AM and Hohnloser SH: Torsade de pointes tachycardia as a rare manifestation of acute enteroviral myocarditis. Heart 86: 489-490, 2001.
30. Gowani SA, Kumar A, Arora S and Lahiri B: Legionella pneumonia complicated by myocarditis and torsades de pointes: A case report and review of literature. Conn Med 77: 331-334, 2014.
31. Sayar N, Terzi S, Yilmaz HY, Atmaca H, Kocak F, Dayi SU, Cakmak N, Tarhan A, Ozler A and Yesilcimen K: A case of prosthetic mitral valve Brucella endocarditis complicated with torsades de pointes. Heart Vessels 21: 331-333, 2006.
32. Adlan AM, Panoulas VF, Smith JP, Fisher JP and Kitas GD: Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis. J Rheumatol 42: 421-428, 2015.
33. Medenwald D, Kors JA, Loppnow H, Thiery J, Kluttig A, Nuding S, Tiller D, Greiser KH, Werdan K and Haerting J: Inflammation and prolonged QT time: Results from the cardiovascular disease, living and ageing in Halle (CARLA) study. PLoS ONE 9: e95994, 2014.
34. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG and Mann DL: Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 103: 2055-2059, 2001.
35. Streitner F, Kuschyk J, Veltmann C, Ratay D, Schoene N, Streitner I, Brueckmann M, Schumacher B, Borggrefe M and Wolpert C: Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm. Cytokine 47: 166-172, 2009.
36. Gupalo EM, Kostyukevich MV, Mironova NA, Shlevkov NB, Kiktev VG, Bakalov SA, Sharf TV, Efremov EE, Chumachenko PV, Kotina ED, Ostroumov EN and Shumakov DV: Electrical storm due to myocarditis in post-infarct patient: When two diseases meet. Cor et Vasa doi:10.1016/j.crvasa.2015.05.006.
37. Robertson MJ, Kline J, Struemper H, Koch KM, Bauman JW, Gardner OS, Murray SC, Germaschewski F, Weisenbach J, Jonak Z and Toso JF: A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin's lymphoma. J Immunother 36: 331-341, 2013.
38. Mattson K, Niiranen A, Pyrhonen S, Farkkila M and Cantell K: Recombinant interferon-γ treatment in non-small cell lung cancer. Antitumor effect and cardiotoxicity. Acta Oncol 30: 607-610, 1991.
39. Lazzerini PE, Acampa M, Capecchi PL, Fineshi I, Selvi E, Moscadelli V, Zimbone S, Gentile D, Galeazzi M and Laghi-Pasini F: Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: Tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res 67: 332-339, 2015.
40. London B, Baker LC, Lee JS, Shusterman V, Choi BR, Kubota T, McTiernan CF, Feldman AM and Salama G: Calcium-dependent arrhythmias in transgenic mice with heart failure. Am J Physiol Heart Circ Physiol 284: H431-H441, 2003.
41. Wang J, Wang H, Zhang Y, Gao H, Nattel S and Wang Z: Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: Role of reactive oxygen species as a mediator. J Biol Chem 279: 13289-13292, 2004.
42. + current in cultured neonatal rat cardiomyocytes: A possible cause of electrical remodeling in diseased hearts. Circulation 70: 605-609, 2006.
43. Fernandez-Velasco M, Ruiz-Hurtado G, Hurtado O, Moro MA and Delgado C: TNFα down-regulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation. Am J Physiol Heart Circ Physiol 293: H238-H245, 2007.
44. Petkova-Kirova PS, Gursoy E, Mehdi H, McTiernan CF, London B and Salama G: Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 290: H2098-H2107, 2006.
45. + currents are reduced in mice with elevated levels of serum TNFα. J Mol Cell Cardiol 47: 238-246, 2009.
46. Li YH and Rozanski GJ: Effects of human recombinant interleukin-1 on electrical properties of guinea pig ventricular cells. Cardiovasc Res 27: 525-530, 1993.
47. 2+]i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol 43: 710-716, 2007.
48. Sun H, Xia M, Shahane SA, Jadhav A, Austin CP and Huang R: Are hERG channel blockers also phospholipidosis inducers? Bioorg Med Chen Lett 23: 4587-4590, 2013.
49. Reasor MJ, McCloud CM, DiMatteo M, Schafer R, Ima A and Lemaire I: Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats. Proc Soc Exp Biol Med 211: 346-352, 1996.
50. Reinhart PG and Gairola CG: Amiodarone-induced pulmonary toxicity in Fischer rats: Release of tumor necrosis factor alpha and transforming growth factor beta by pulmonary alveolar macrophages. J Toxicol Environ Health 52: 353-365, 1997.
51. Masubuchi H, Ueno M, Maeno T, Hara K, Suzuki M, Kono S, Yamaguchi A, Yamaguchi K, Kanbe M, Kitahara S, Orii M, Aoki N, Aoki F, Suga T and Kurabayashi M: Pathological analysis of amiodarone-induced lung injury. Am J Respir Crit Care Med 189: A5734, 2014.
52. Munic V, Banjanac M, Kostrun S, Nujic K, Bosnar M, Marjanovic N, Ralic J, Martijasic M, Hlevnjak M and Haber VE: Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis. Pharmocol Res 64: 298-307, 2011.
53. Shayman JA and Abe A: Drug induced phospholipidosis: An acquired lysosomal storage disorder. Biochem Biophys Acta 1831: 602-611, 2013.
54. Anderson N and Borlak J: Drug-induced phospholipidosis. FEBS Lett 580: 5533-5540, 2006.
55. Kitatani K, Idkowiak-Baldys J and Hannun YA: The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 20: 1010-1018, 2008.
56. Nioi P, Perry BK, Wang EJ, Gu YZ and Snyder RD: In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid-based methodologies. Toxicol Sci 99: 162-173, 2007.
57. Grandl M, Liebisch G, Robenek H, Rubsamen K, Boettcher A, Englmaier M and Schmitz G: Ox-LDL induces endolysosomal phospholipidosis and ceramide species while E-LDL induces lipid droplets and cholesterylester in human macrophages. Chem Phys Lipids 163s: s40, 2010.
58. Hiraoka M, Abe A, Lu Y, Yang K, Han X, Gross RW and Shayman JA: Lysosomal phospholipase A2 and phospholipidosis. Mol Cell Biol 26: 6139-6148, 2006.
59. Abe A, Hiraoka M and Shayman JA: A role for lysosomal phospholipase A2 in drug induced phospholipidosis. Drug Metab Lett 1: 49-53, 2007.
60. Lecommandeur E: Ceramide metabolism in the liver and its role in two lysosomal lipidoses: Drug-induced phospholipidosis and Sandhoff disease. Metabomeeting, 10-12 September, London 2014.
61. Bismuth J, Lin P, Yao Q and Chen C: Ceramide: A common pathway for atherosclerosis? Atherosclerosis 196: 497-504, 2008.
62. Galadari S, Rahman A, Pallichankandy S, Galadari A and Thayyullathil F: Role of ceramide in diabetes mellitus: Evidence and mechanisms. Lipids Health Dis 12: 98, 2013.
63. Saddoughi SA and Ogretmen B: Diverse function of ceramide in cancer cell death and proliferation. Adv Cancer Res 117: 37-58, 2013.
64. Ogretman B and Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Rev Cancer 4: 604-616, 2004.
65. Schutze S, Machleidt T and Kronke M: The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukoc Biol 56: 533-541, 1994.
66. Wiegmann K, Schultz S, Machleidt T, Witte D and Kronke M: Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78: 1005-1015, 1994.
67. Dressler KA, Mathias S and Kolesnick RN: Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. Science 255: 1715-1718, 1992.
68. Kuno K and Matsushima K: The IL1 receptor signaling pathway. J Leukoc Biol 56: 542-547, 1994.
69. Xu J, Yeh CH, Chen S, He L, Sensi SL, Canzoniero LM, Choi DW and Hsu CY: Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death. J Biol Chem 273: 16521-16526, 1998.
70. Modur V, Zimmerman GA, Prescott SM and McIntyre TM: Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. J Biol Chem 271: 13094-13102, 1996.
71. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJ and Sabbadini RA: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 98: 2854-2865, 1996.
72. Ruvolo PP: Ceramide regulates cellular homeostasis via diverse stress signaling pathways. Leukemia 15: 1153-1160, 2001.
73. Hanna AN, Chan EY, Xu J, Stone JC and Brindley DN: A novel pathway for tumor necrosis factor-alpha and ceramide signaling involving sequential activation of tyrosine kinase, p21(ras), and phosphatidylinositol 3-kinase. J Biol Chem 274: 12722-12729, 1999.
74. Lopez-Marure R, Ventura JL, Sanchez L, Montano LF and Zentella A: Ceramide mimics tumour necrosis factor-alpha in the induction of cell-cycle arrest in endothelial cells. Induction of the tumour suppressor p53 with decrease in retinoblastoma/ protein levels. Eur J Biochem 267: 4325-4333, 2000.
75. Michael JM, Lavin MF and Watters DJ: Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling. Cancer Res 57: 3600-3605, 1997.
76. Dbaibo GS, Obeid LM and Hannun YA : Tumor necrosis factor-α (TNFα) signal transduction through ceramide. J Biol Chem 268: 17762-17766, 1993.
77. Raines MA, Kolesnick RN and Golde DW: Sphingomyelinase and ceramide activate mitogen-activated protein kinase in myeloid HL-60 cells. J Biol Chem 268: 14572-14575, 1993.
78. + channel by ceramide: Evidence for ubiquitin-mediated lysosomal degradation. J Cell Sci 118: 5325-5334, 2005.
79. Wu SN, Lo YK, Kuo BI and Chiang HT: Ceramide inhibits the inwardly rectifying potassium current in GH(3) lactotrophs. Endocrinology 142: 4785-4794, 2001.
80. + channel dysfunction. Cell Physiol Biochem 20: 429-440, 2007.
81. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S and Spiegel S: Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800-803, 1996.
82. Maceka M, Payne SG, Milstien S and Spiegel S: Sphingosine kinase, sphingosine-1-phosphate and apoptosis. Biochim Biophys Acta 1585: 193-201, 2002.
83. Spiegel S and Milstien S: Sphingosine-1-phosphate: An enigmatic signaling lipid. Nature Rev Mol Cell Biol 4: 397-407, 2003.
84. Conrath CE, Wilde AAM, Jongbloed RJE, Alders M, van Langen IM, van Tintelen JP, Doevendans PA and Opthof T: Gender differences in the long QT syndrome: Effects of β-adrenoceptor blockade. Cardiovasc Res 53: 770-776, 2002.
85. Nakagawa M, Ooie T, Takahashi N, Taniguchi Y, Anan F, Yonemochi H and Saikawa T: Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol 29: 607-613, 2006.
86. Odening KE, Choi BR and Koren G: Sex hormones and cardic arrest in long QT syndrome: Does progesterone represent a potential new antiarrhythmic therapy? Heart Rhythm 9: 1150-1152, 2012.
87. Kadish AH, Greenland P, Limacher MC, Frishman WH, Daugherty SA and Schwartz JB: Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol 9: 366-374, 2004.
88. Nakamura H, Kurokawa J, Bai CX, Asada K, Xu J, Oren RV, Zhu ZI, Clancy CE, Isobe M and Furukawa T: Progesterone regulates cardiac repolarization through a nongenomic pathway: An in vitro patch-clamp and computational modeling study. Circulation 116: 2913-2922, 2007.
89. Odening KE, Choi BR, Liu GX, Hartmann K, Ziv O, Chaves L, Schofield L, Centracchio J, Zehender M, Peng X, Brunner M and Koren G: Estradiol promotes sudden cardiac death in transgenic long QT type 2 rabbits while progesterone is protective. Heart Rhythm 9: 823-832, 2012.
90. Aisemberg J, Vercelli CA, Bariani M V, Billi SC, Wolfson ML and Franchi AM: Progesterone is essential for protecting against LPS-induced pregnancy loss. LIF as a potential mediator of the anti-inflammatory effect of progesterone. PLoS ONE 8: e56161, 2013 doi:10.1371/journal.pone.0056161.
91. Loudon JAZ, Elliot CL, Hills F and Bennett PR: Progesterone represses interleukin-8 and cyclo-oxygenase-2 in human lower segment fibroblast cells and amnion epithelial cells. Biol Reprod 69: 331-337, 2003.
92. He J, Evans CO, Hoffman SW, Oyesiku NM and Stein DG: Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol 189: 404-412, 2004.
93. Chen G, Shi J, Jin W, Wang L, Xie W, Sun J and Hang C: Progesterone administration modulates TLRs/NF-κB signaling pathway in rat brain after cortical contusion. Ann Clin Lab Sci 38: 65-74, 2008.
94. Pan DS, Liu WG, Yang XF and Cao F: Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury. Biomed Environ Sci 20: 432-438, 2007.
95. Giannoni E, Guignard L, Knaup Reymond M, Perreau M, Roth-Kleiner M, Calandra T and Roger T: Estradiol and progesterone strongly inhibit the innate immune response of newborn mononuclear cells. Infect Immun doi:10.1128/IAI.00076-11, 2011.
96. Jeng YJ, Suarez VR, Izban MG, Wang HQ and Soloff MS: Progesterone-induced sphingosine kinase-1 expression in the rat uterus during pregnancy and signaling consequences. Am J Physiol Endocrinol Metab 292: E1110-E1121, 2007.
97. Holland WL and Scherer PE: PAQRs: A counteracting force to ceramides? Mol Pharmacol 75: 740-743, 2009.
98. Moussatche P and Lyons TJ: Non-genomic progesterone signaling and its non-canonical receptor. Biochem Soc Trans 40: 200-204, 2012.
99. Wang Y, Wang X, Lau WB, Yuan Y, Booth D, Li JJ, Scalia R, Preston K, Gao E, Koch W and Ma XL: Adiponectin inhibits tumor necrosis factor-α induced vascular inflammatory response via caveolin-mediated ceramidase recruitment and activation. Circ Res 114: 792-805, 2014.
100. Thomas P and Pang Y: Membrane progesterone receptors: Evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells. Neuroendorinology 96: 162-171, 2012.
101. Kupchak BR, Garitaonandia I, Villa N Y, Smith JL and Lyons TJ: Antagonism of human adiponectin receptors and their membrane progesterone receptor paralogs by TNFα and a ceramidase inhibitor. Biochemistry 48: 5504-5506, 2009.
102. Buechler C, Wanninger J and Neumeier M: Adiponectin receptor binding proteins - recent advances in elucidating adiponectin signaling pathways. FEBS Lett 584: 4280-4286, 2010.
103. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA and Scherer PE: Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nature Med 17: 55-63, 2011.
104. Morad SAF and Cabot MC: Ceramide-orchestrated signaling in cancer cells. Nature Rev Cancer 13: 51-65, 2013.
105. Furlong SJ, Mader JS and Hoskin DW: Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol Rep 15: 1385-1390, 2006.
106. Wegner MS, Wanger RA, Oertel S, Brachtendorf S, Hartmann D, Schiffmann S, Marschalek R, Schreiber Y, Ferreiros N, Geisslinger G and Grosch S: Ceramide synthases CerS4 and CerS5 are upregulated by 17β-estradiol and GPER1 via AP-1 in human breast cancer cells. Biochem Pharmacol 92: 577-589, 2014.
107. Schiffmann S, Sandner J, Birod K, Wobst I, Angioni C, Ruckhaberle E, Kauffmann M, Ackermann H, Lotsch J, Schmidt H, Geisslinger G and Grosch S: Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 30: 745-752, 2009.
108. Li JJ, Li YS, Chu JM, Zhang CY, Wang Y, Huang Y, Chen J, Yuan JQ and Huang YL: Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta 366: 269-273, 2006.
109. Lai WT, Lee KT, Chu CS, Voon WC, Yen HW, Tsai LY and Sheu SH: Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: An effect independent on cholesterol elevation. Int J Cardiol 98: 459-464, 2005.
110. Lee KT, Lai WT, Chu CS, Tsai LY, Yen HW, Voon WC and Sheu SH: Effect of withdrawal of statin on C-reactive protein. Cardiology 102: 166-170, 2004.
111. Li B, Mahmood A, Lu D, Wu H, Xiong Y, Qu C and Chopp M: Simvastatin attenuates microglia, astrocyte activation and decreases IL1β level following traumatic brain injury. Neurosurgery 65: 179-186, 2009.
112. Chen SF, Hung TH, Chen CC, Lin KH, Huang YN, Tsai HC and Wang JY: Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. Life Sci 81: 288-298, 2007.
113. Wang H, Lynch JR, Song P, Yang HJ, Yates RB, Mace B, Warner DS, Guyton JR and Laskowitz DT: Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol 206: 59-69, 2007.
114. Iwata A, Shirai R, Ishii H, Kushima H, Otani S, Hashinaga K, Umeki K, Kishi K, Tokimatsu I, Hiramatsu K and Kadota J: Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clin Exp Immunol 168: 234-240, 2012.
115. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, Anzueto A and Pugh JA: Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalized with pneumonia. Eur Respir J 31: 611-617, 2008.
116. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP and Sorensen HT: Pre-admission use of statin and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 168: 2081-2087, 2008.
117. Chalmers JD, Singanayagam A, Murray MP and Hill AT: Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 121: 1002-1007, 2008.
118. Dobesh PP, Klepser DG, McGuire TR, Morgan CW and Olsen KM: Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 29: 621-630, 2000.
119. Almog Y, Shefer A, Novak V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L and Danon A: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110: 880-885, 2004.
120. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V and Radovancevic B: Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Cardiac Failure 11: 684-690, 2005.
121. Mark L and Katona A: Effect of fluvastatin on QT dispersion: A new pleiotropic effect? Am J Cardiol 85: 919-920, 2000.
122. Chiu JH, Abdelhadi RH, Chung MK, Gurm HS, Marrouche NF, Saliba WJ, Natale A and Martin DO: Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 95: 490-491, 2005.
123. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP and Elisaf MS: Do statins have an antiarrhythmic activity? Cardiovasc Res 75: 10-20, 2007.
124. Buber J, Goldenberg I, Moss AJ, Wang PJ, McNitt S, Hall J, Eldar M, Barsheshet A and Schecter M: Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Am Coll Cardiol 60: 749-755, 2012.
125. Barsheshet A, Wang PJ and Moss AJ: MADIT-CRT investigators reverse remodeling and the risk of ventricular tachyarrhythmias in MADIT-CRT. J Am Coll Cardiol 57: 2416-2423, 2011.
126. Egom EE, Rose RA, Neyses L, Soran H, Cleland JG and Mamas MA: Activation of sphingosine-1-phosphate signaling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Crit Rev Clin Lab Sci 50: 79-89, 2013.
127. Igarashi J, Miyoshi M, Hashimoto T, Kubota Y and Kosaka H: Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol 150: 470-479, 2007.
128. Sugiura T, Dohi Y, Yamashita S, Ohte N, Ito S, Iwaki S, Hirowatari Y, Ohkawa R, Mishima Y, Yatomi Y, Kimura G and Fujii S: Analytical evaluation of plasma serotonin and sphingosine 1-phosphate and their clinical assessment in early atherosclerosis. Coron Artery Dis 23: 234-238, 2012.
129. Chen SD, Hu CJ, Yang DI, Nassief A, Chen H, Yin K, Xu J and Hsu CY: Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF1 activation and VEGF up-regulation. Ann NY Acad Sci 1042: 357-364, 2005.
130. Wei YM, Li X, Xiong J, Abais JM, Xia M, Boini KM, Zhang Y and Li PL: Attenuation by statins of membrane raft-redox signaling in coronary arterial endothelium. J Pharmacol Exp Ther 345: 170-179, 2013.
131. Shopp G, Helson L, Bouchard A, Salvail and Majeed M: Liposomes ameliorate crizotinib- and nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation. Anticancer Res 34: 4733-4740, 2014.
132. Helson L, Shopp G, Bouchard A and Majeed M: Liposome mitigation of curcumin inhibition of cardiac potassium delayed-rectifier current. J Recept Ligand Channel Res 5: 1-8, 2012.
133. Ranjan AP, Mukerjee A, Helson L and Vishwanatha JK: Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation. J Nanobiotechnol 11: 40, 2013.
134. Helson L, Sordillo PP, Schopp G, Savail D, Bouchard A, Shaw WA, Burgess SW, Kloesch B and Majeed M: Liposomal curcumin (Lipocurc) and in vitro/in vivo surrogates for cytokine storm associated with uncontrolled Ebola infection. Targeting Ebola Paris 2015, Recent Advances and Strategies, May 28-29, 2015.
135. Martin WJ, Kachel DL, Vilen T and Natarajan V: Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J Pharmacol Exp Ther 251: 272-278, 1989.
136. Punithavathi D, Venkatesan N and Babu M: Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. Br J Pharmacol 139: 1342-1350, 2003.
137. Stein O, Oette K, Dabach Y, Hollander G, Ben Naim M and Stein Y: Persistence of increased cholesteryl ester in human skin fibroblasts is caused by residual exogenous sphingomyelinase and is reversed by phospholipid liposomes. Biochim Biophys Acta 1165: 153-159, 1992.
138. Gupta AK and Rudney H: Plasma membrane sphingomyelin and the regulation of HMG-CoA reductase activity and cholesterol biosynthesis in cell cultures. J Lipid Res 32: 125-136, 1991.
139. Liu JJ, Nilsson A and Duan RD: Effects of phospholipids on sphingomyelin hydrolysis induced by intestinal alkaline sphingomyelinase: An in vitro study. J Nutr Biochem 11: 192-197, 2000.
140. Zhang Y, Sun X, Zhang Y, Wang J, Lu Y, Yang B and Wang Z: Potential therapeutic value of antioxidants for abnormal prolongation of QT interval and the associated arrhythmias in a rabbit model of diabetes. Cell Physiol Biochem 28: 97-102, 2011.
141. Bednarz B, Chamiec T and Ceremuzynski L: Antioxidant vitamins decrease exercise-induced QT dispersion after myocardial infarction. Kardiol Pol 58: 375-379, 2003.
142. Kuklinski B, Weissenbacher E and Fahnrich A: Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol Aspects Med 15: S143-S147, 1994.
143. Odermarsky M, Lykkesfeldt J and Liuba P: Poor vitamin C status is associated with increased carotid intima-media thickness, decreased microvascular function, and delayed myocardial repolarization in young patients with type 1 diabetes. Am J Clin Nutr 90: 447-452, 2009.
144. Bezombes C, Plo I, Mansat-De Mas V, Quillet-Mary A, Negre-Salvayre A, Laurent G and Jaffrezou JP: Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C. FASEB J doi.10.1096/fj.00-0787fje, 2001.
145. Sawada M, Nakashima S, Kiyono T, Nakagawa M, Yamada J, Yamakawa H, Banno Y, Shinoda J, Nishimura Y, Nozawa Y and Sakai N: p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells. Oncogene 20: 1368-1378, 2001.
146. Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P and Grant S: The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Molec Pharmacol 69: 216-225, 2006.
147. Manago A, Becker KA, Carpinteiro A, Wilker B, Soddemann M, Seitz AP, Edwards MJ, Grassme H, Szabo I and Gulbins E: Pseudomonas aeruginosa pyocyanin induces neutrophil death via mitochondrial reactive oxygen species and mitochondrial acid sphingomyelinase. Antioxid Redox Signal 22: 1097-1110, 2015.
148. Hatanaka Y, Fujii J, Fukutomi T, Watanabe T, Che W, Sanada Y, Igarashi Y, Taniguchi N: Reactive oxygen species enhances the induction of inducible nitric oxide synthase by sphingomyelinase in RAW264.7 cells. Biochim Biophys Acta 1393: 203-210, 1998.
149. Castillo SS, Levy M, Thaikoottathil JV and Goldkorn T: Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells. Exp Cell Res 313: 2680-2686, 2007.
150. Hernandez OM, Discher DJ, Bishopric NH and Webster KA: Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res 86: 198-204, 2000.
151. Yamagata K, Ichinose S, Tagawa C and Tagami M: Vitamin E regulates SMase activity, GSH levels, and inhibit neuronal death in stroke-prone spontaneously hypertensive rats during hypoxia and reoxygenation. J Exp Stroke Trans Med 2: 41-48, 2009.
152. Gu X, Song X, Dong Y, Cai H, Walters E, Zhang R, Pang X, Xie T, Guo Y, Sridhar R and Califano JA: Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 14: 1840-1848, 2008.
153. Vejux A, Guyot S, Montange T, Riedinger JM, Kahn E and Lizard G: Phospholipidosis and down-regulation of the PI3-K/PDK-1/AKT signaling pathway are vitamin E inhibitable events associated with 7-ketocholesterol-induced apoptosis. J Nutr Biochem 20: 45-61, 2009.
154. Navas P, Villalba JM and de Cabo R: The importance of plasma membrane coenzyme Q in aging and stress responses. Mitochondrion 7: S34-S40, 2007.
155. Dumitru CA and Gulbins E: TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis. Oncogene 25: 5612-5625, 2006.
156. Woo CH, Eom YW, Yoo MH, You MH, Han HJ, Song WK, Yoo YJ, Chun JS and Kim JH: Tumor necrosis factor-alpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J Biol Chem 275: 32357-32362, 2000.
157. Kim JJ, Lee SB, Park JK and Yoo YD: TNFα-induced ROS production triggering apoptosis is directly linked to ROMO1 and BCL-X(L). Cell Death Differ 17: 1420-1434, 2010.
158. Yang D, Elner SG, Bian ZM, Till GO, Petty HR and Elner VM: Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 85: 462-472, 2007.
159. Lo YYC and Cruz TF: Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol Chem 270: 11727-11730, 1995.
160. Sultan I, Senkal CE, Ponnusamy S, Bielawski J, Szulc Z, Bielawska A, Hannun YA and Ogretman B: Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function. Biochem J 393: 513-521, 2006.
161. Son JH, Yoo HH and Kim DH: Activation of de novo synthetic pathway of ceramides is responsible for the initiation of hydrogen peroxide-induced apoptosis in HL-60 cells. J Toxicol Environ Health A 70: 1310-1318, 2007.
162. Meyer SGE and de Groot H: Cycloserine and threo-dihydrosphingosine inhibit TNFα-induced cytotoxicity: Evidence for the importance of de novo ceramide synthesis in TNFα signaling. Biochimica et Biophysica Acta 1643: 1-4, 2003.
163. Sawada M, Kiyono T, Nakashima S, Shinoda J, Naganawa T, Hara S, Iwama T and Sakai N: Molecular mechanisms of TNFα-induced ceramide formation in human glioma cells: P53-mediated oxidant stress-dependent and-independent pathways. Cell Death Differ 11: 997-1008, 2004.
164. Maceyka M, Milstien S and Spiegel S: Shooting the messenger: Oxidative stress regulates sphingosine-1-phosphate. Circ Res 100: 7-9, 2007.
165. Pchejetski D, Kunduzova O, Dayon A, Calise D, Seguelas MH, Leducq N, Seif I, Parini A and Cuvillier O: Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 100: 41-49, 2007.
166. Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD, Licamele L, Polymeropoulos H and Lavedan C: Whole-genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 14: 1024-1031, 2009.
167. + currents via a Ras- and Raf-1-dependent pathway in cultured oligodendrocytes. J Neurosci 18: 8712-8719, 1998.
168. Chik CL, Li B, Karpinski E and Ho AK: Ceramide inhibits the outward potassium current in rat pinealocytes. J Neurochem 79: 339-348, 2001.
169. Ganapathi SB, Fox TE, Kester M and Elmslie KS: Ceramide modulates HERG potassium channel gating by translocation into lipid rafts. Am J Physiol 299: C74-C86, 2010.
170. Camgoz A, Gencer EB, Ural AU, Avcu F and Baran Y: Roles of ceramide synthase and ceramide clearance genes in nilotinib-induced cell death in chronic myeloid leukemia cells. Leuk Lymphoma 52: 1574-1584, 2011.
171. Baran Y, Camgoz A, Gencer E, Ural A and Avcu F: A novel mechanism of nilotinib-induced apoptosis, bioactive sphingolipids. Haematologica 95: 528, 2010.
172. El-Algamy DS: Nilotinib ameliorates lipopolysaccharide-induced acute lung injury in rats. Toxicol Appl Pharmacol 253: 153-160, 2011.
173. Gencer EB, Ural AU, Avcu F and Baran Y: A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. Ann Hematol 90: 1265-1275, 2011.
174. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM and Ogretmen B: Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 282: 10922-10934, 2007.
175. Baran Y, Bielawski J, Gunduz U and Ogretmen B: Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol 137: 1535-1544, 2011.
176. Huang WC, Tsai CC, Chen CL, Chen TY, Chen YP, Lin YS, Lu PJ, Lin CM, Wang SH and Tsao CW: Glucosylceramide synthesis inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to BCR-ABL inhibitor and cooperatively induces glycogen synthase kinase-3 regulated apoptosis. FASEB J 25: 3661-3673, 2011.
177. Gao H and Deng L: Sphingosine kinase-1 activation causes acquired resistance against sunitinib in renal cell carcinoma cells. Cell Biochem Biophys 68: 419-425, 2014.
178. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C and Gault CR: Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl stability and drug resistance by modulation of protein phosphatase 2A. Blood 117: 5941-5952, 2011.
179. Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, Melo JV and Cuvillier O: Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 22: 971-979, 2008.
180. Ekiz HA and Baran Y: Therapeutic applications of bioactive sphingolipids in hematological malignancies. Int J Cancer 127: 1497-1506, 2010.
181. Unlu M, Kiraz Y, Kaci FN, Ozcan MA and Baran Y: Multidrug resistance in chronic myeloid leukemia. Turk J Biol 38: 806-816, 2014.
182. Jozefowski S, Czerkies M, Lukasik A, Bielawski A, Bielawski J, Kwaitkowska K and Sobota A: Ceramide and ceramide 1-phosphate are negative regulators of TNFα production induced by lipopolysaccharide. J Immunol 185: 6960-6973, 2010.
183. Rozenova KA, Deevska GM, Karakashian AA and Nikolova-Karakashian MN: Studies on the role of acid sphingomyelinase and ceramide in the regulation of tumor necrosis factor alpha (TNFα)-converting enzyme activity and TNFα secretion in macrophages. J Biol Chem 285: 21103-21113, 2010.
184. Walton KA, Gugiu BG, Thomas M, Basseri RJ, Eliav DR, Salomon RG and Berliner JA: A role for neutral sphingomyelinase activation in the inhibition of LPS action by phospholipid oxidation products. J Lipid Res 47: 1967-1974, 2006.
185. Jung JS, Shin KO, Lee YM, Shin JA, Park EM, Jeong J, Kim DH, Choi JW and Kim HS: Anti-inflammatory mechanism of exogenous C2 ceramide in lipopolysaccharide-stimulated microglia. Biochim Biophys Acta 1831: 1016-1026, 2013.
186. Goldsmith M, Avni D, Levy-Rimler G, Mashiach R, Ernst O, Levi M, Webb B, Meijler MM, Gray NS, Rosen H and Zor T: A ceramide-1-phosphate analogue, PCERA-1, simultaneously suppresses tumour necrosis factor-α and induces interleukin-10 production in activated macrophages. Immunology 127: 103-115, 2008.
187. Abboushi N, El-Hed A, El-Assaad W, Kozhaya L, El-Sabban ME, Bazarbachi A, Badreddine R, Bielawski A, Usta J and Dbaibo GS: Ceramide inhibits IL2 production by preventing protein kinase C-dependent NF-κB activation: Possible role in protein kinase Cθ regulation. J Immunol 173: 3193-3200, 2004.
188. Sun Y, Fox T, Adhikary G, Kester M and Pearlman E: Inhibtion of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol 83: 1512-1521, 2008.
189. Fujita H, Kitawaki T, Sato T, Maeda T, Kamihira S, Takaori-Kondo A and Kadowaki N: The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA. Eur J Immunol 43: 93-103, 2013.
190. Canals D, Perry DM, Jenkins RW and Hannun YA: Drug targeting of sphingolipid metabolism: Sphingomyelinases and ceramidases. Br J Pharmacol 163: 694-712, 2011.
191. Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Muhle C, Terfloth L, Groemer TW, Spitzer GM, Liedl KR, Gulbins E and Tripal P: Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One 6: e23852, 2011.
192. Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC, Mahdy A, Zeidan Y, Bielwaska A, Hannun YA and Norris JS: New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 580: 4751-4756, 2006.
193. Canoso RT and Sise HS: Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol 13: 121-129, 1982.
194. Pretel M, Marques L and Espana A: Drug-induced lupus erythematosus. Actas Dermosifiliogr 105: 18-30, 2014.
195. Hieronymus T, Grotsch P, Blank N, Grunke M, Capraru D, Geiler T, Winkler S, Kalden JR and Lorenz HM: Chlorpromazine induces apoptosis in activated human lymphoblasts: A mechanism supporting the induction of drug-induced lupus erythematosus. Arthritis Rheum 43: 1994-2004, 2000.
196. Delgado A, Casas J, Llebaria A, Abad JL and Fabrias G: Inhibitors of sphingolipid metabolism enzymes. Biochim Biophys Acta Biomembranes 1758: 1957-1977, 2006.
197. Kolzer M, Werth N and Sandhoff K: Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett 559: 96-98, 2004.
198. Hurwitz R, Ferlinz K and Sandhoff K: The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 375: 447-450, 1994.
199. Pankova-Kholmyansky I and Flescher E: Potential new antimalarial chemotherapeutics based of sphingolipid metabolism. Chemotherapy 52: 205-209, 2006.
200. Labaied M, Dagan A, Dellinger M, Geze M, Egee S, Thomas SL, Wang C, Gatt S and Grellier P: Anti-plasmodium activity of ceramide analogs. Malaria J 3: 49, 2004.
201. Sharma N: Inhibiton of tumor cell growth by mefloquine via multimechanistic effects involving increased cellular stress, inhibition of autophagy, and impairment of cellular energy metabolism. Ph.D. Thesis, University of Southern California, 3564014, 2013.
202. Frolov RV, Ignatova II and Singh S: Inhibition of HERG potassium channels by celecoxib and its mechanism, PLoS One 6: e26344, 2011.
203. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking AKT activation in human prostate cancer cells independently of BCL-2. J Biol Chem 275: 11397-11403, 2000.
204. Kundu N, Smyth MJ, Samsel L and Fulton AM: Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat 76: 57-64, 2002.
205. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
206. Schiffmann S, Ziebell S, Sandner J, Birod K, Deckmann K, Hartmann D, Rode S, Schmidt H, Angioni C, Geisslinger G and Grosch S: Activation of ceramide synthase-6 by celecoxib leads to a selective induction of C16:0-ceramide. Biochem Pharmacol 80: 1632-1640, 2010.
207. Yagi Y, Nakamura Y, Kitahara K, Harada T, Kato K, Ninomiya T, Cao X, Ohara H, Izumi-Nakaseko H, Suzuki K, Ando K and Sugiyama A: Analysis of onset mechanisms of a sphingosine-1-phosphate receptor modulator fingolimod-induced atrioventricular conduction block and QT-interval prolongation. Toxicol Appl Pharmacol 281: 39-47, 2014.
208. Camm J, Hla T, Bakshi R and Brinkmann V: Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications. Amer Heart J 168: 632-644, 2014.
209. Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N and Kantor D: Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors. Mult Scler Relat Disord 4: 273-280, 2015.
210. Mori M: Lethal arrthymia due to fingolimod, a S1P receptor modulator: Are we overestimating or underestimating? J Neurol Neurosurg Psychiatry doi:10.1136/jnnp-2015-310451, 2015.
211. Thangada S, Shapiro LH, Silva C, Yamase H, Hla T and Ferrer FA: Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction. J Urol 191: 1508-1516, 2014.
212. Chiba K, Kataoka H, Seki N, Shimano K, Koyama M, Fukunari A, Sugahara K and Sugita T: Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol 11: 366-372, 2011.
213. Oldstone MBA and Rosen H: Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. In: Sphingosine-1-Phosphate Signaling in Immunology and Infectious Diseases. MBA Oldstone and H Rosen (eds.). Switzerland, Springer, 2014.
214. Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, Watanabe T, Hatta M, Shinya K, Suresh M, Kawaoka Y, Rosen H and Oldstone MBA: Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci USA 108: 12018-12023, 2011.
215. Oldstone MB and Rosen H: Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol 378: 129-147, 2014.
216. Van Brocklyn JR and Williams JB: The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of cell survival and death. Comp Biochem Physiol B Biochem Mol Biol 163: 26-36, 2012.
217. Dawson G and Qin J: Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic anti-depressants. Biochem Biophys Res Commun 404: 321-323, 2011.
218. Codini M, Cataldi S, Ambesi-Impiombato FS, Lazzarini A, Floridi A, Lazzarini R, Curcio F, Beccari T and Albi E: Gentamicin arrests cancer cell growth: The intriguing involvement of nuclear sphingomyelin metabolism. Int J Mol Sci 16: 2307-2319, 2015.
219. Ghosh P and Chatterjee S: Effects of gentamicin on sphingomyelinase activity in cultured human renal proximal tubular cells. J Biol Chem 262: 12550-12556, 1987.
220. Naeem U, Waheed A and Bakhtiar S: Determination of the effects of ciprofloxacin in prevention of aminoglycoside induced nephrotoxicity in rabbits: A comparative study. Pakistan J Pharmacol 27: 1-10, 2010.
221. Beauchamp D, Laurent G, Grenier L, Gourde P, Zanen J, Heuson-Stiennon JA and Bergeron MG: Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin. Antimicrob Agents Chemother 41: 1237-1245, 1997.
222. Morad SAF, Levin JC, Shanmugavelandy SS, Kester M, Fabrias G, Bedia C and Cabot MC: Ceramide-antiestrogen nanoliposomal combinations-Novel impact of hormonal therapy in hormone-insensitive breast cancer. Mol Cancer Ther 11: 2352-2361, 2012.
223. Albi E and Magni MV: Sphingolipid metabolism inhibitors and cell function. Open Enzyme Inhibition J 1: 72-79, 2008.
224. Robert J: MS-209 Schering. Curr Opin Investig Drugs 5: 1340-1347, 2004.
225. Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Muller S, Jaffrezou JP and Laurent G: Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 15: 1166-1173, 2004.
226. Zeidan YH, Jenkins RW and Hannun YA: Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol 181: 335-350, 2008.
227. Rebillard A, Rioux-Leclercq N, Muller C, Bellaud P, Jouan F, Meurette O, Jouan E, Vernhet L, Le Quement C, Carpinteiro A, Schenck M, Lagadic-Gossmann D, Gulbins E and Dimanche-Boitrel MT: Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage. Oncogene 27: 6590-6595, 2008.
228. Maurmann L, Belkacemi L, Adams NR, Majmudar PM, Moghaddas S and Bose RN: A novel cisplatin-mediated apoptosis pathway is associated with acid sphingomyelinase and FAS proapoptotic protein activation in ovarian cancer. Apoptosis 20: 960-974, 2015.
229. Petersen NHT, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lonborg A, Vindelov SD, Hanahan D, Arenz C, Ejsing CS, Kirkegaard T, Rohde M, Nylandsted J and Jaattela M: Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 24: 379-393, 2013.
230. 2+ channel in the plasma membrane of Leishmania Mexicana. Biochem Biophys Res Commun 430: 1091-1096, 2013.
231. Hazar-Rethinam M, de Long LM, Gannon OM, Topkas E, Boros S, Vargas AC, Dzienis M, Mukhopadhyay P, Simpson F, Endo-Munoz L and Saunders NA: A novel E2F/sphingosine kinase-1 axis regulates anthracycline response in squamous cell carcinoma. Clin Cancer Res 21: 417-427, 2015.
232. Mansat V, Bettaieb A, Levade T, Laurent G and Jaffrezou JP: Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. FASEB J 11: 695-702, 1997.
233. Straub AC, Klei LR, Stolz DB and Barchowsky A: Arsenic requires sphingosine-1-phosphate type 1 receptors to induce angiogenic genes and endothelial cell remodeling. Am J Pathol 174: 1949-1958, 2009.
234. Park MT, Kang YH, Park IC, Kim CH, Lee YS, Chung HY and Lee SJ: Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells. Mol Cancer Ther 6: 82-92, 2007.
235. Senchenkov A, Litvak DA and Cabot MC: Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst 93: 347-357, 2001.
236. Senkal CE, Ponnusamy S, Rossi MJ, Bialewski J, Sinha D, Jiang JC, Jazwinski SM, Hannun YA and Ogretmen B: Role of human longevity assurance gene-1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 6: 712-722, 2007.
237. Kroesen BJ, Pettus B, Luberto C, Busman M, Siestma H, de Leij L and Hannun YA: Induction of apoptosis through B-cell receptor cross-linking occurs via de novo-generated C16-ceramide and involves mitochondria. J Biol Chem 276: 13606-13614, 2001.
238. Veret J, Coant N, Berdyshev E V, Skobeleva A, Therville N, Bailbe D, Gorshkova I, Natarajan V, Portha B and Le Stunff H; Ceramide synthase 4 and de novo production of ceramides with specific N-acyl chain lengths are involved in glucolipotoxicity-induced apoptosis of INS-1 β-cells. Biochem J 438: 177-189, 2011.
239. Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Bronneke HS, Trifunovic A, LoSasso G, Wunderlich FT, Kornfeld JW, Bluher M, Kronke M and Bruning JC: Obesity-induce CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 20: 678-686, 2014.
240. Mielke MM, Maetzler W, Haughey NJ, Bandaru VVR, Savica R, Deuschle C, Gasser T, Hauser AK, Graber-Sultan S, Schleicher E, Berg D and Liepelt-Scarfone I: Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: A pilot study. PLoS One 8: e73094, 2013.
241. Grosch S, Schiffman S and Geisslinger G: Chain length-specific properties of ceramides. Prog Lipid Res 51: 50-62, 2012.
242. Cutler RG, Kelly J, Storie K, Pedersen WA , Tammara A, Hatanpaa K, Troncoso JC and Mattson MP: Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101: 2070-2075, 2004.
243. Paschall AV, Zimmerman MA, Torres CM, Yang D, Chen MR, Li X, Bieberich E, Bai A, Bielawski J, Bielawski A and Liu K: Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression. BMC Cancer 14: 24, 2014.
244. Aflaki E, Doddapattar P, Radovic B, Povoden S, Kolb D, Vujic N, Wegscheider M, Koefeler H, Hornemann T, Graier WF, Malli R, Madeo F and Kratky D: C16 ceramide is crucial for triacylglycerol-induced apoptosis in macrophages. Cell Death Dis 3: e280, 2012 .
245. Seumois G, Fillet M, Gillet L, Faccinetto C, Desmet C, Francois C, Dewals B, Oury C, Vanderplasschen A, Lekeux P and Bureau F: De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis. J Leukoc Biol 81: 1477-1486, 2007.
246. Sassa T, Suto S, Okayasu Y and Kihara A: A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells. Mol Cell Biol Lipids 1821: 1031-1037, 2012.
247. Stiban J and Perera M: Very long chain ceramides interfere with C16-ceramide-induced channel formation: A plausible mechanism for regulating the initiation of intrinsic apoptosis. Biochim Biophys Acta Biomembranes 1848: 561-567, 2015.
248. Di Paola M, Cocco T and Lorusso M: Ceramide interaction with the respiratory chain of heart mitochondria. Biochemistry 39: 6660-6668, 2000.
249. Monette JS, Gomez LA, Moreau RF, Dunn KC, Butler JA, Finlay LA, Michels AJ, Shay KP, Smith EJ and Hagen TM: (R)-α-Lipoic acid treatment restores ceramide balance in aging rat cardiac mitochondria. Pharmacol Res 63: 23-29, 2011.
250. Russo SB, Baicu CF, Van Laer A, Geng T, Kasiganesan H, Zile MR and Cowart LA: Ceramide synthase-5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest 122: 3919-3930, 2012.
251. Bock J, Szabo I, Gamper N, Adams C and Gulbins E: Ceramide inhibits the potassium channel Kv1.3 by the formation of membrane platforms. Biochem Biophys Res Commun 305: 890-897, 2003.
252. White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L and Voelkel-Johnson C: Ceramide synthase-6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 28: 1132-1141, 2009.
253. Osawa Y, Uchinami H, Bielawski J, Schwabe RF, Hannun YA and Brenner DA: Mechanisms of signal transduction: Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-α. J Biol Chem 280: 27879-27887, 2005.
254. Schiffmann S, Ferreiros N, Birod K, Eberle M, Schreiber Y, Pfeilschifter W, Ziemann U, Pierre S, Scholich K, Grosch S and Geisslinger G: Ceramide synthase-6 plays a critical role in the development of experimental autoimmune encephalomyelitis. J Immunol 188: 5727-5733, 2012.
255. Futerman AH (Ed.): Ceramide Signaling. Kluwer Academic, Plenum Publishers 2002.
256. Alemany R, Kleuser B, Ruwisch L, Danneberg K, Lass H, Hashemi R, Spiegel S, Jacobs KH and Meyer zu Heringdorf D: Depolarization induces rapid and transient formation of intracellular sphingosine-1-phosphate. FEBS Lett 509: 239-244, 2001.
257. Dbaibo GS, Kfoury Y, Darwiche N, Panjarian S, Kozhaya L, Nasr R, Abdallah M, Hermine O, El-Sabban M, de The H and Bazarbachi A: Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica 92: 753-762, 2007.
258. Sun WY, Abeynaike LD, Escarbe S, Smith CD, Pitson SM, Hickey MJ and Bonder CS: Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent. Am J Pathol 180: 1740-1750, 2012.
259. Cabot MC, Giuliano AE, Han TY and Liu YY SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res 59: 880-885, 1999.
260. Astarita G, Avanesian A, Grimaldi B, Realini N, Justinova Z, Panlilio LV, Basit A, Goldberg SR and Piomelli D: Methamphetamine accelerates cellular senescence through stimulation of de novo ceramide biosynthesis. PLoS One 10: e0116961, 2015.
261. Kurita-Ochiai T, Amano S, Fukushima K and Ochiai K: Cellular events in butyric acid-induced T cell apoptosis. J Immunol 171 : 3576-3584, 2003.
262. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S and Grant S: The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64: 2590-2600, 2004.
263. Muscoli C, Doyle T, Dagostino C, Bryant L, Chen Z, Watkins L, Ryerse J, Bieberich E, Neumman W and Salvemini D: Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J Neurosci 30: 15400-15408, 2010.
264. Ndengele MM, Cuzzocrea S, Masini E, Vinci MC, Esposito E, Muscoli C, Petrusca DN, Mollace V, Mazzon E, Li D, Petrache I, Matuschak GM and Salvemini D: Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther 329: 64-75, 2009.
265. Moussavi M, Assi K, Gomez-Munoz A and Salh B: Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 27: 1636-1644, 2006.
266. Gong L, Yang B, Xu M, Cheng B, Tang X, Zheng P, Jing Y and Wu GJ: Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemother Pharmacol 73: 69-77, 2014.
267. Liu GY, Han F, Yang Y, Xie Y, Jiang H, Mao YY, Wang HP, Wang MM, Chen R, Yang J and Chen JH: Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of rapamycin. Nephrol Dial Transplant 26: 1493-502, 2010.
268. Linardic CM, Jayadev S and Hannun YA: Activation of the sphingomyelin cycle by brefeldin A: Effects of brefeldin A on differentiation and implications for a role for ceramide in regulation of protein trafficking. Cell Growth Differ 7: 765-774, 1996.
269. Mandala SM, Thornton RA, Milligan J, Rosenbach M, Garcia-Calvo M, Bull HG, Harris G, Abruzzo GK, Flattery AM, Gill CJ, Bartizal K, Dreikorn S and Kurtz MB: Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase. J Biol Chem 273: 14942-14949, 1998.
270. Zager RA: Polyene antibiotics: Relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content. Am J Kidney Dis 36: 238-249, 2000.
271. Zollinger M, Gschwind HP, Jin Y, Sayer C, Zecri F and Hartmann S: Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: A case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metab Dispos 39: 199-207, 2011.